Simulations Plus, Inc. (NASDAQ:SLP) Short Interest Up 29.1% in January

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 1,420,000 shares, an increase of 29.1% from the December 31st total of 1,100,000 shares. Based on an average daily volume of 251,600 shares, the short-interest ratio is presently 5.6 days. Currently, 8.6% of the company's stock are short sold.

Simulations Plus Stock Up 1.9 %

Shares of NASDAQ SLP traded up $0.69 during trading hours on Wednesday, reaching $36.19. 180,761 shares of the stock traded hands, compared to its average volume of 301,464. The company has a market capitalization of $727.13 million, a P/E ratio of 90.48 and a beta of 0.83. Simulations Plus has a 52-week low of $24.00 and a 52-week high of $51.22. The company's 50-day simple moving average is $30.56 and its two-hundred day simple moving average is $32.42.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the sale, the director now owns 3,402,584 shares in the company, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 19.40% of the company's stock.

Hedge Funds Weigh In On Simulations Plus

A number of institutional investors have recently added to or reduced their stakes in SLP. First Horizon Advisors Inc. boosted its stake in shares of Simulations Plus by 82.6% during the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company's stock worth $26,000 after acquiring an additional 370 shares during the last quarter. nVerses Capital LLC boosted its stake in Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company's stock valued at $38,000 after buying an additional 1,100 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Simulations Plus in the third quarter valued at $59,000. US Bancorp DE increased its holdings in shares of Simulations Plus by 37.0% in the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company's stock worth $159,000 after buying an additional 1,343 shares during the last quarter. Finally, Pitcairn Co. lifted its stake in shares of Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company's stock valued at $211,000 after purchasing an additional 549 shares during the last quarter. Institutional investors own 78.08% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. BTIG Research reduced their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a "buy" rating for the company in a research report on Thursday, October 24th. Stephens began coverage on Simulations Plus in a research note on Friday, November 15th. They issued an "overweight" rating and a $39.00 price target for the company. William Blair reiterated an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. StockNews.com cut Simulations Plus from a "hold" rating to a "sell" rating in a research note on Monday, November 4th. Finally, KeyCorp boosted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.